» Articles » PMID: 34822316

Orodispersible Tablets for Pediatric Drug Delivery: Current Challenges and Recent Advances

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2021 Nov 25
PMID 34822316
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Child appropriate dosage forms are indispensable in modern medicine and are a prerequisite for successful pediatric drug therapy. For years, experts have called for a paradigm shift, from liquid dosage forms to novel oral solid dosage forms. This review aims to shed light on recent developments in Orodispersible tablets (ODTs) and mini-tablets (ODMTs).

Areas Covered: This review focuses on the presentation and critical discussion of current challenges as well as recent advances in ODTs for pediatric drug delivery. Highlighted aspects are the evidence for acceptability by children, e.g. in comparison to other dosage forms, and limitations given by tablet size at different ages, as well as advances in special ODT formulations (taste masking, modified release, enabling formulations).

Expert Opinion: It is the authors' belief that OD(M)Ts have significant potential as dosage forms in pediatric therapy that has not yet been fully exploited. The reasons for this are, first, that the number of direct acceptance studies is extremely low and the resulting knowledge is therefore rather anecdotal. Despite the high relevance, there seems to be reluctance both in the therapeutic use and conduction of respective studies in children. However, if one combines the knowledge from the few existing studies, surveys, and from approved products, it becomes apparent that so far there is no evidence on limitations of the use of ODTs in pediatric patients.

Citing Articles

Pediatric Orally Disintegrating Tablets (ODTs) with Enhanced Palatability Based on Propranolol HCl Coground with Hydroxypropyl-β-Cyclodextrin.

Cirri M, Mura P, Maestrelli F, Benedetti S, Buratti S Pharmaceutics. 2024; 16(11).

PMID: 39598476 PMC: 11597579. DOI: 10.3390/pharmaceutics16111351.


Development and Evaluation of an Orodispersible Tablet Formation for the Delivery of a Hydrophobic Drug.

Haddad R, Gardouh A Adv Pharmacol Pharm Sci. 2024; 2024:7914860.

PMID: 39450401 PMC: 11502129. DOI: 10.1155/2024/7914860.


Leading Paediatric Infectious Diseases-Current Trends, Gaps, and Future Prospects in Oral Pharmacotherapeutic Interventions.

Rampedi P, Ogunrombi M, Adeleke O Pharmaceutics. 2024; 16(6).

PMID: 38931836 PMC: 11206886. DOI: 10.3390/pharmaceutics16060712.


Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.

Golhen K, Buettcher M, Kost J, Huwyler J, Pfister M Pharmaceutics. 2023; 15(4).

PMID: 37111519 PMC: 10143173. DOI: 10.3390/pharmaceutics15041033.


Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.

Cornila A, Iurian S, Tomuta I, Porfire A Pharmaceutics. 2022; 14(8).

PMID: 36015247 PMC: 9414456. DOI: 10.3390/pharmaceutics14081621.